This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Impax Laboratories Reports Third Quarter 2012 Results

Global Pharmaceuticals Division Information

      Three Months Ended       Nine Months Ended

(unaudited, amounts in thousands)

September 30, September 30,
2012     2011 2012     2011
Revenues:
Global Product sales, net $ 99,463 $ 97,661 $ 342,105 $ 301,124
Rx Partner (792 ) 12,621 4,652 20,169
OTC Partner 763 879 2,237 4,006
Research Partner   996     3,385   7,765   13,154
Total revenues 100,430 114,546 356,759 338,453
Cost of revenues   44,106     54,196   177,690   164,627
Gross profit   56,324     60,350   179,069   173,826
Operating expenses:
Research and development 12,392 11,487 35,190 34,728
Patent litigation (recovery) expense (371 ) 2,114 6,581 6,097
Selling, general and administrative   3,790     3,694   11,482   8,892
Total operating expenses   15,811     17,295   53,253   49,717
Income from operations $ 40,513   $ 43,055 $ 125,816 $ 124,109
 

Global Pharmaceuticals Division revenues in the third quarter 2012 were $100.4 million, compared to $114.5 million in the prior year period, primarily due to lower Rx Partner and Research Partner revenues.

2 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,911.65 -158.75 -0.88%
S&P 500 2,091.79 -22.70 -1.07%
NASDAQ 4,940.3570 -76.5720 -1.53%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs